Two neuraminidase inhibitors for treatment of influenza

Article Abstract:

The FDA has approved zanamivir for the treatment of influenza. Sold under the trade name Relenza, it inhibits a viral enzyme called neuraminidase. This in turn decreases viral shedding. It comes in the form of dry powder and is inhaled through the mouth using a Diskhaler much like the treatment of asthma. Studies have shown it can prevent influenza in those exposed to it and decreases symptoms. The FDA will probably also approve oseltamivir, which will be sold under the trade name Tamiflu.

Evaluation, Product/Service Evaluation, Drug therapy, Influenza, Zanamivir, Relenza (Medication)

---

Influenza vaccine, 1999-2000

Article Abstract:

A new influenza vaccine is available for the 1999-2000 flu season. It contains the antigens A/Beijing/262/95-like (H1N1), A/Sydney/5/97-like (H3N2), and B/Yamanashi/166/98. It is recommended for the elderly and patients at high risk of contracting the flu and everyone who comes in contact with them. Health care personnel should also be vaccinated. The best time to vaccinate is from October through mid-November.

Composition

---

Problems with influenza vaccine

Article Abstract:

There may be a shortage of influenza vaccine in the US this winter. Until adequate supplies are available, only elderly patients, high-risk patients, and their contacts should be vaccinated.

Supply and demand

Similar abstracts:

• Abstracts: Clinical manifestations and treatment of dysfunctional uterine bleeding. Clinical Features and Treatment of Peristomal Pyoderma Gangrenosum
• Abstracts: Sex and urinary tract infections. Human metapneumovirus--an important new respiratory virus. Asymptomatic bacteriuria -- important or not?

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.